Biomedical subjects

M Monreal Bosch

Publications and source records attributed to M Monreal Bosch.

7 recordsLinked to original sources

PubMed2006

[Current indications of heparin treatment].

The last guidelines on treatment of venous thromboembolic disease recommend the use of unfractionated heparin (UFH) or low molecular weight heparin (LMWH). In the case of deep venous thrombosis in out-patients, LMWH is preferred, associated to dicumarinics from the first day. In regards to prophylaxis, administration of UFH or LMWH is recommended in surgical patients of moderate to high risk but not in those undergoing minor surgery, under 40 years and without other risk factors. In patients with acute coronary syndrome without ST elevation, the administration of LMWH at fixed doses together with platelet antiaggregants is recommended. In patients with acute cerebral ischemia and without other criteria for thrombolytic treatment, treatment with heparin is not recommended but rather the administration of platelet antiaggregants.

Anticoagulants↗

PubMed2003

[Computerized registry of patients with thromboembolic disease in Spain (RIETE): background, objectives, methods, and preliminary results].

BACKGROUND: Venous thromboembolic disease (VTD) is a common and severe condition. Its anticoagulation-based treatment is not without complications and failures. OBJECTIVE: To create in Internet a broad database of patients with venous thromboembolic disease attended at spanish hospitals which might be helpful in the clinical practice. METHODS: Computerized registry of all incident cases of patients with objective diagnosis of VTD attended at 27 spanish hospitals since March, 1st, 2001. All data related to diagnosis, treatment and follow-up during at least a 3-month period were collected. RESULTS: Since March 1st to August 31st, 2001, 573 patients were included (399 with VTD, 108 with PE and 66 with VTD and PE). The mean age of patients was 65.8 years. 10.5 % of patients had at least one risk factor: 5.2% hypoprothrombinemia (< 50%), 3% history of recent hemorrhage, 1.8% creatinine higher than 3 mg/dl, 1.3% hemodynamic unstability, 1.1% pregnancy, and 1% thrombopenia lower than 60000 platelets/mm3. The three-month follow-up period was completed by 35.4% of patients, 21.8 % of them with events (death [4.7%], hemorrhage [12.5%], and VTD relapse [4.2%]). Hypoprothrombinemia was significantly associated with increased risk of complications and history of recent hemorrhage with relapse. CONCLUSIONS: It is feasible to create a database containing information on a relevant number of VTD patients, 10.5% of them with complications. Such information will allow its utilization at short-term for the decision-marking process, particularly for patients with complications.

Adolescent↗

PubMed2000